Oxford Biomedica’s (OXB) interim results highlight strong operational and financial momentum to date. The Novo Holdings equity investment (£53.5m) in May has enabled OXB to fully repay the debt facility, effectively strengthening the balance sheet. It is investing ahead of increasing demand for its lentiviral vector manufacturing capacity with the build-out of OxBox. The new facility will more than double capacity and is expected to be ready for commercial vector production in H12
01 Oct 2019
Oxford Biomedica - Investing for future growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oxford Biomedica - Investing for future growth
Oxford BioMedica plc (OXB:LON) | 207 5.2 1.2% | Mkt Cap: 207.3m
- Published:
01 Oct 2019 -
Author:
Dr Daniel Wilkinson -
Pages:
8
Oxford Biomedica’s (OXB) interim results highlight strong operational and financial momentum to date. The Novo Holdings equity investment (£53.5m) in May has enabled OXB to fully repay the debt facility, effectively strengthening the balance sheet. It is investing ahead of increasing demand for its lentiviral vector manufacturing capacity with the build-out of OxBox. The new facility will more than double capacity and is expected to be ready for commercial vector production in H12